companiesCompany

Autolus Therapeutics

UCL spin-out whose fast-off-rate CD19 CAR-T, obe-cel, was approved for adult ALL in 2024 with lower neurotoxicity than earlier products.

Obecabtagene autoleucel (Aucatzyl) approved 8 November 2024 (US) and 2025 (UK/EU) for relapsed/refractory adult B-ALL on FELIX; trials in lupus and paediatric ALL. Manufacturing in Stevenage.

Headquarters

London, GB

Type

cell therapy · AUTL

Website

www.autolus.com

Products

1top

ApprovedCAR-T (CD19, fast off-rate)

Obecabtagene autoleucel · Aucatzyl

A CD19 CAR-T built to grip and release quickly, which cut severe side effects and gave adults with relapsed ALL a real chance at durable remission.

Connected

3top

Autolus Therapeutics

Products

Connected

cancers

fronts

drugs